Replies to post #252 on Equity Field Notes from temporal sources

[DanWebzster]

FENC is a biotech with one valuable product and dwindling cash

Pedmark is a Breakthrough Therapy that protects pediatric cancer patients against Cisplatin-induced hearing loss.

FENC anticipates filing an NDA for Pedmark H2/18.

The best outcome for shareholders would be a buy out. FENC does not have the capital necessary to market the drug.

Some believe that FENC could fetch $12-15/share without further dilution.

[DanWebzster]